Form 4: Avalo Therapeutics CLO Equity Transaction

Chief Legal Officer Paul Varki disposed of 1,081 shares of Avalo Therapeutics common stock to cover tax obligations.

Summary

• Paul Varki, Chief Legal Officer of Avalo Therapeutics, Inc., reported the disposition of 1,081 shares of common stock.
• The transaction occurred on June 10, 2026, at a price of $13.10 per share.
• The disposition was executed to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 32,576 shares of common stock.
• The total includes 5,723 shares acquired through the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event, as the share disposition was strictly for tax withholding purposes.

Positives

• The reporting person maintains a significant equity stake of 32,576 shares, aligning interests with shareholders.
• The acquisition of 5,723 shares via the Employee Stock Purchase Plan indicates continued participation in the company's equity incentive programs.

Negatives

• The transaction represents a reduction in the direct holdings of a key executive.

Risks

• General market volatility affecting the valuation of equity-based compensation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine Form 4 filings involving tax withholding upon equity vesting are standard corporate governance practices and generally do not signal a change in executive sentiment regarding company performance.

Comparison to Industry Standards

• The transaction follows standard industry practices for executive tax compliance related to equity compensation plans.
• The retention of 32,576 shares suggests a standard level of executive 'skin in the game' for a company of this size.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related disposition.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Insider Trading, Form 4, Equity Compensation, Chief Legal Officer